Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/219426
Title: Everolimus through plasmatic concentrations in cancer patients: prospective longitudinal observational multicentric study (DIANA-1 Project)
Author: Fort Casamartina, Eduard
Pernas, Sònia
Otero Torres, Sara
Mate, Paula
Gonzalo, Núria
Narváez, Sonia
Rigo Bonnin, Raúl
Padró i Miquel, Ariadna
Teulé Vega, Àlex
García del Muro Solans, Xavier
Peiró Martínez, Inmaculada
Arribas, Lorena
Esteve, Anna
González, Andrea
Rey, Montse
Clopés Estela, Ana
Fontanals Martínez, Sandra
Muñoz, Carmen
Keywords: Càncer
Immunosupressors
Posologia
Cancer
Immunosupressive agents
Posology
Issue Date: 1-Jan-2025
Publisher: MDPI
Abstract: Background: Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), is actually used to prevent organ transplant rejection and treat metastatic breast, renal, and neuroendocrine cancers. Despite significant pharmacokinetic variability among patients, routine therapeutic drug monitoring (TDM) is not commonly used in oncology. Methods: The aim of this multicenter, prospective observational cohort study is to assess the prevalence of everolimus minimum concentration at a steady state (Cminss) falling outside the therapeutic range (10-26.3 ng/mL) during a routine TDM programme. Sixty patients with metastatic breast, neuroendocrine, or renal cancers, either starting or continuing everolimus treatment according to hospital protocols, are to be included between 1st of January 2024 and 31st of December 2025 (patients undergoing clinical trials are excluded). We hypothesize that 30-50% of our patients and their blood samples will not achieve the target optimal plasma concentrations. Blood samples are collected every 4-6 weeks to monitor drug levels. The secondary goal is to explore correlation between out-of-range everolimus levels and factors such as demographic and anthropometric data, treatment specifics, lab results, genetic polymorphisms, and the presence of toxicity. Conclusions: This study could offer valuable insights into optimizing dosing strategies and may contribute to future research on personalizing everolimus and other anticancer treatments. This personalized approach seeks to tailor therapy not only to the tumour's molecular profile but also to the individual characteristics of each patient, improving both drug selection and dosing precision.
Note: Reproducció del document publicat a: https://doi.org/10.3390/jcm14010145
It is part of: Journal of Clinical Medicine, 2025, vol. 14, num.1
URI: https://hdl.handle.net/2445/219426
Related resource: https://doi.org/10.3390/jcm14010145
ISSN: 2077-0383
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
890189.pdf591.65 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons